The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns

Thrombosis Research

Volumn 89, Issue 5, 1998, Pages 211-215

  Larsen, Torben B ^a   Lassen, Jens F ^a   Brandslund, Ivan ^a   Byriel, Lene ^a   Petersen, Gert Bruun ^a   Nørgaard Pedersen, Bent ^b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

APC resistance; Factor V; Gender; Infancy; Mutation; Prevalence; Thrombosis

Indexed keywords

ARGININE; BLOOD CLOTTING FACTOR 5 LEIDEN; GLUTAMINE;

ACTIVATED PROTEIN C RESISTANCE; AMINO ACID SUBSTITUTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; FEMALE; GENE FREQUENCY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN SCREENING; PHENYLKETONURIA; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; SWEDEN; THROMBOEMBOLISM;

COHORT STUDIES; DENMARK; FACTOR V; FEMALE; FETAL DEATH; GENE FREQUENCY; HUMANS; INFANT, NEWBORN; MALE; NEONATAL SCREENING; POINT MUTATION; PROTEIN C; SEX; THROMBOEMBOLISM;

EID: 0032029880     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00010-3     Document Type: Article

References (33)

1. Koster T., Rosendaal F.R., De Ronde H., Briet E., Vandenbroucke J.P., Bertine R.M. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden Thrombophilia Study Lancet. 342:1993;1503-1506.
2. Dahlbäck B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Prediction of a cofactor to activated protein C Proc Natl Acad Sci USA. 90:1993;1004-1008.
3. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., De Ronde H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
4. Zöller B., Berntsdotter A., Garcia De Frutos P., Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 85:1995;3518-3523.
5. Schröder W., Koessling M., Wulff K., Wehnert M., Herrmann F.H. World distribution of factor V Leiden mutation. Lancet. 347:1996;59.
6. Ridker P.M., Hennekens C.H., Lindpaintner K., Stampfer M.J., Eisenberg P.R., Miletich J.P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 332:1995;912-917.
7. Rees D.C., Cox M., Clegg J.B. World distribution of factor V Leiden. Lancet. 346:1995;1133-1134.
8. Chaida C., Gialeraki A., Tsoukala C., Mandalaki T. Prevalence of the FVQ506 mutation in the Hellenic population. Thromb Haemost. 76:1996;127. (letter).
9. Dzimiri N., Meyer B. World distribution of factor V Leiden. Lancet. 347:1996;481-482.
10. Takamiya O., Ishida F., Kodaira H., Kitano K. APC-resistance and MnlI Genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost. 74:1995;996.
11. Beauchamp N.J., Daly M.E., Hampton K.K., Cooper P.C., Preston F.E., Peake I.R. High prevalence of a mutation in the factor V gene within the U.K. population. Relationship to activated protein C resistance and familial thrombosis Br J Haematol. 88:1994;219-222.
12. De Maat M.P.M., Kluft C., Jespersen J., Gram J. World distribution of factor V Leiden mutation. Lancet. 347:1996;58-59.
13. Olivieri O., Friso S., Manzato F.et al. Resistance to activated protein C in healthy women taking oral contraceptives. British Journal of Haematology. 91:1995;465-470.
14. Zöller B., Hillarp A., Dahlbäck B. Activated protein C resistance caused by a common factor V mutation has a single origin. Thromb Res. 85:1997;237-243.
15. Svensson P.J., Zöller B., Mattiasson I., Dahlbäck B. The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med. 241:1997;379-385.
16. Ridker P.M., Miletich J.P., Hennekens C.H., Buring J.E. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 277:1997;1305-1307.
17. Hooper W.C., Dilley A., Ribeiro M.J., Benson J., Austin H., Silva V. A racial difference in the prevalence of the Arg506→Gln mutation. Thromb Res. 81:1996;577-581.
18. Hellgren M., Svensson P.J., Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 173:1995;210-213.
19. De Stefano V., Mastrangelo S., Paciaroni K., Ireland H., Lane D.A., Scirpa P. Thrombotic risk during pregnancy and puerperium in women with APC-resistance - Effective subcutaneous heparin prophylaxis in a pregnant patient. Thromb Haemost. 74:1995;793-794.
20. Grisaru D., Fait G., Eldor A. Activated protein C resistance and pregnancy complications. Am J Obstet Gynecol. 174(2):1996;801-802.
21. Dizon Townson D.S., Nelson L.M., Easton K., Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol. 175:1996;902-905.
22. Brenner B., Mandel H., Lanir N., Younis J., Rothbart H., Ohel G. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol. 97:1997;551-554.
23. Zöller B., Svensson P.J., He X., Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 94:1994;2521-2524.
24. Sinclair A.H., Berta P., Palmer M.S., Hawkins J.R., Griffiths B.L., Smith M.J. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature. 346:1990;240-244.
25. Armitage P., Berry G. Statistical Methods in Medical Research. 2:1987;Blackwell Scientific Publications, Oxford. p. 101.
26. Armitage P, Berry G. Statistical Methods in Medical Research. 2nd ed. Oxford: Blackwell Scientific Publications, 1987. pp. 482-3.
27. Armitage P, Berry G. Statistical Methods in Medical Research. 2nd ed. Oxford: Blackwell Scientific Publications, 1987. pp. 205-208.
28. Tosetto A., Missiaglia E., Gatto E., Rodeghiero F. The VITA Project. Phenotypic resistance to activated protein C and FV Leiden mutation in the general population Thromb Haemost. 78:1997;859-863.
29. Bokarewa M.I., Bremme K., Falk G., Sten-Linder M., Egberg N., Blomback M. Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene. Thromb Res. 78:1995;193-200.
30. Rand J.H., Wu X., Andree H.A.M., Lockwood C.J., Guller S., Scher J. Pregnancy loss in the antiphospholipid-antibody syndrome - A possible thrombogenic mechanism. N Engl J Med. 337(3):1997;154-160.
31. Malm J., Laurell M., Dahlbäck B. Changes in the plasma levels of vitamin K-dependent protein C and S of CB4-binding protein during pregnancy and oral contraception. Br J Haematol. 68:1988;437-443.
32. Zöller B., Holm J., Svensson P.J., Dahlbäck B. Elevated levels of protrombin activation fragment 1+2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost. 75(2):1996;270-274.
33. Schipper R.F., Oudshoorn M., D'amaro J., Van Der Zanden H.G., De Lange P., Bakker J.T. Validation of large data sets, an essential prerequisite for data analysis. An analytical survey of the bone marrow donors worldwide Tissue Antigens. 47:1996;169-178.